论文部分内容阅读
急性冠脉综合征(ACS)是心内科常见急症。药物涂层支架及抗血小板药物的不断更新,使ACS病人经皮冠状动脉介入治疗术后缺血事件的发生率大幅度降低,但与治疗相伴随的出血并发症却逐渐增加,成为ACS治疗中发生率最高的并发症之一。出血引起贫血或基线水平贫血的ACS病人构成了冠心病又一高危人群。输血作为贫血和急性出血治疗手段并不能明显改善患者预后,但已被纳入评价该类病人危险分层的指标。
Acute coronary syndrome (ACS) is a common emergency in cardiology. Drug-coated stents and anti-platelet drugs continue to update the ACS patients with percutaneous coronary intervention after a significant reduction in the incidence of ischemic events, but accompanied with the treatment of bleeding complications have gradually increased, as ACS treatment One of the most frequent complications. Patients with bleeding from anemia or baseline anemia constitute another high-risk group of coronary heart disease. Transfusion as anemia and acute hemorrhage does not significantly improve the prognosis of patients, but has been included in the evaluation of the risk stratification of such patients indicators.